Copenhagen Nanomedicine Day

November 2019: Attending the Copenhagen Nanomedicine Day at University of Copenhagen, CSO Klaus Gregorius will give a talk on how MipSalus uses phenylalanine-binding polymer nano-particles as a medicinal product for the treatment of PKU patients.

The 33rd E.S.PKU Conference

November 2019: MipSalus attends the 33rd E.S.PKU (European Society for Phenylketonuria and Allied Disorders Treated as Phenylketonuria) conference in Izmir, Turkey. The conference assembles patients, organizations and professionals, and CSO Klaus Gregorius will give a presentation on MipSalus´ breakthrough treatment of PKU and the progression of the drug development process.

Expansion of working facilities

October 2019: MipSalus increases its facilities at DTU Science Park (previously Scion DTU) including a new laboratory and extra office space for the company´s latest employees.

MipSalus closes a private placement

July 2019: MipSalus closes a private placement from private investors.

MipSalus receives a grant to develop a treatment for AKU

March 2019: MipSalus has received a DKK 0.5 million grant from Innovation Fund Denmark to develop a treatment for the ultra rare genetic disease Alkaptonuria (AKU), also known as Black Bone Disease. People affected by AKU lacks enough functional level of the enzyme required to break down homogentisic acid. Over time, the accumulation of homogentisic acid in the body leads to black and brittle bones and cartilage, and early onset osteoarthritis.

The first known medicinal treatment for AKU, nitisinone, leads to condition called nitisinone-induced hypertyrosinaemia, meaning that nitosinone causes the build-up of the amino acid tyrosine in the blood system. As a consequence of the accumulation of tyrosine, AKU patients face the same health problems as PKU patients and must thus follow a heavily protein-reduced diet. The treatment which MipSalus aims to develop will allow nitisinone-treated AKU patients to consume normal diet.